Global Blood Therapeutics, Inc.
GBTNASDAQHealthcare
$68.49
+$0.01(+0.01%)
Market Cap$0
P/E Ratio—
52W High$73.02
52W Low$21.65
Global Blood Therapeutics, Inc. (GBT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GBT · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2021-12 | 2020-12 | 2019-12 | 2018-12 | 2017-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19B | $0.12B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.19B | $0.12B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | 98.30% | 98.40% | 97.72% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.21B | $0.16B | $0.17B | $0.13B | $0.09B |
| G&A Expenses | $0.00B | $0.00B | $0.12B | $0.05B | $0.03B |
| Total Operating Expenses | $0.48B | $0.37B | $0.29B | $0.18B | $0.12B |
| Operating Income | ($0.29B) | ($0.24B) | ($0.28B) | ($0.18B) | ($0.12B) |
| Operating Margin %(computed) | -147.44% | -196.42% | — | — | — |
| Interest Income | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.30B) | ($0.25B) | ($0.27B) | ($0.17B) | ($0.12B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.30B) | ($0.25B) | ($0.27B) | ($0.17B) | ($0.12B) |
| Net Margin %(computed) | -155.63% | -199.96% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.82 | $-4.04 | $-4.57 | $-3.41 | $-2.76 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.05B | 0.04B |
| EBITDA | ($0.28B) | ($0.23B) | ($0.26B) | ($0.17B) | ($0.12B) |
| EBITDA Margin %(computed) | -143.02% | -183.29% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Global Blood Therapeutics, Inc. data
About Global Blood Therapeutics, Inc. (GBT) Income Statement
Global Blood Therapeutics, Inc. (GBT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2021, GBT reported revenue of $0.19B, gross profit of $0.19B (gross margin 98.30%), and net income of ($0.30B) — a net profit margin of -155.63%.
Frequently asked questions
GBT · 4 questionsGlobal Blood Therapeutics, Inc. (GBT) reported revenue of $0.19B for 2021, up 57.3% year-over-year.
GBT revenueGBT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09